BioSpace News Archive

A robust corporate affairs function plays an integral role in building a biopharmaceutical company’s reputation and brand.

Deer Lake First Nation celebrates the transfer of their community primary care services from Indigenous Services Canada to Keewaytinook Okimakanak (KO). Community primary care services will now be delivered using a new service delivery model developed by KO in collaboration with its member communities.

The Prader-Willi California Foundation will hold its 18th Annual Walking for Prader-Willi Syndrome events on April 29 at Griffith Park in Los Angeles, May 5 at the Clovis Trail Fest, and June 2 at Lagoon Park in San Rafael to raise awareness of Prader-Willi syndrome.

The NASH Network (NASHNET), in collaboration with The Kinetix Group will be participating at the upcoming International Liver Congress, hosted by the European Association for the Study of the Liver (EASL) on April 11th - 15th at Paris Expo Porte de Versailles in Paris, France.

Susan G. Komen® has partnered with Pfizer® to present a line-up of educational events, held in local communities across the United States and aimed at helping improve the lives of women and men living with metastatic breast cancer (MBC).

Oragenics, Inc. announced that it has entered into a securities purchase agreement with certain new institutional investors providing for the purchase and sale of 900,000 shares of common stock at a price of $2.00 per share in a registered direct offering.

Clovis Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca® (rucaparib) tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

NueHealth Holdings announced with great pleasure the addition of three proven Healthcare Executives to senior executive positions.

Pfizer Canada announced today that Health Canada has approved BESPONSA™ (inotuzumab ozogamicin for injection) as a monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).1 BESPONSA is the first and only CD22-directed antibody-drug conjugate approved for this indication.

Northwestern Medicine’s Innovation Department, in partnership with Northwestern Memorial Foundation and Superior Ambulance, recently hosted the second annual Northwestern Medicine Innovation Challenge Grant Final Event.